Skip to content

Effect of Ayurvedic line of Management in adenoid enlargement in children.

Effectiveness of selected Ayurveda management protocol in adenoid hypertrophy among children of age group 5 to 10 years. - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090098
Enrollment
23
Registered
2025-07-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J352- Hypertrophy of adenoids

Interventions

None listed

Sponsors

Dr. Musafar Ahammed
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of adenoid hypertrophy with breathing difficulty. Patients between age group 5 years to 10 years, irrespective of gender, religion, and socio-economic status.

Exclusion criteria

Exclusion criteria: Diagnosed cases of systemic disorders like renal and cardiac diseases Diagnosed cases malignancy, TB, anemia and bleeding disorders. Use of corticosteroids in all forms within 3 months of enrolment Participants with Infectious adenoid hypertrophy. Malnourished and underweight children. Children with developmental delay

Design outcomes

Primary

MeasureTime frame
To assess the effect of Varanadi Kashaya, Kanchanara guggulu tablet, Vilwadi tablet and Trikatukadi gandusha followed by Saptamushtika yusha pana and pathyahara and vihara in reducing the symptoms in participants of age group of 5-10 years irrespective of gender diagnosed with adenoid hypertrophy.Timepoint: 0th,30th,60th day

Secondary

MeasureTime frame
To critically study adenoid hypertrophy in an Ayurvedic perspective.Timepoint: 0th,15th,30th, 60th day

Countries

India

Contacts

Public ContactDr Kusumam Joseph

Government Ayurveda Medical College thiruvananthapuram kerala

musafarmarayi2016@gmail.com9496952573

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026